13.55

1.80% 0.24

Pre-market: 13.50 -0.05 -0.37%

Phathom Pharmaceuticals Inc (PHAT)

Overview News Price History Option Chain Financials Discussions Forecast

Phathom Pharmaceuticals Inc stock is traded at $13.55, with a volume of 1.43M. It is up +1.80% in the last 24 hours and up +15.12% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Previous Close:

$13.31

Open:

$14.43

24h Volume:

1.43M

Relative Volume:

1.23

Market Cap:

$961.29M

Revenue:

$114.04M

Net Income/Loss:

$-330.15M

P/E Ratio:

-2.8647

EPS:

-4.73

Net Cash Flow:

$-274.85M

1W Performance:

+0.15%

1M Performance:

+15.12%

6M Performance:

+215.85%

1Y Performance:

-20.99%

1-Day Range:

$13.11

$14.43

1-Week Range:

$13.00

$16.08

52-Week Range:

$2.21

$19.50

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name

Phathom Pharmaceuticals Inc

Sector

Healthcare (1135)

Industry

Biotechnology (635)

Phone

(877) 742-8466

Address

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Employee

427

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PHAT's Discussions on Twitter

Compare PHAT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHAT Phathom Pharmaceuticals Inc	13.55	944.26M	114.04M	-330.15M	-274.85M	-4.73
VRTX Vertex Pharmaceuticals Inc	425.57	107.66B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	651.80	68.74B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	456.04	58.93B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	818.50	50.51B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	189.60	41.29B	447.02M	-1.18B	-868.57M	-6.1812

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight
May-03-24	Initiated	Stifel	Buy
Jan-05-24	Reiterated	Needham	Buy
Aug-09-23	Initiated	H.C. Wainwright	Buy
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral
Feb-17-21	Initiated	BMO Capital Markets	Outperform
Feb-02-21	Initiated	Guggenheim	Buy
Jun-26-20	Downgrade	Goldman	Neutral → Sell
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Goldman	Neutral
Nov-19-19	Initiated	Jefferies	Buy
Nov-19-19	Initiated	Needham	Buy

View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

03:03 AM

How strong is Phathom Pharmaceuticals Inc. stock revenue growthMarket Performance Recap & Breakout Confirmation Alerts - newser.com

03:03 AM

12:37 PM

Can Phathom Pharmaceuticals Inc. recover in the next quarterPortfolio Return Report & Long-Term Safe Investment Ideas - newser.com

12:37 PM

Is Phathom Pharmaceuticals Inc. stock a buy on dipsJuly 2025 Drop Watch & Smart Allocation Stock Reports - newser.com

12:37 PM

12:31 PM

Is Phathom Pharmaceuticals Inc. stock positioned for digital transformation2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com

12:31 PM

Nov 02, 2025

Comparing Phathom Pharmaceuticals Inc. in custom built stock radarsQuarterly Investment Review & Precise Buy Zone Identification - newser.com

Nov 02, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance

Nov 02, 2025

Why Phathom Pharmaceuticals Inc. stock remains a top recommendationWeekly Stock Summary & Short-Term Trading Opportunity Alerts - newser.com

Nov 02, 2025

AlphaQuest LLC Buys 30,760 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat

Nov 02, 2025

Nov 01, 2025

Is Phathom Pharmaceuticals Inc. a candidate for recovery playMarket Growth Review & Detailed Earnings Play Strategies - newser.com

Nov 01, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap UpTime to Buy? - MarketBeat

Nov 01, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 01, 2025

Will Phathom Pharmaceuticals Inc. stock rally after Fed decisions2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com

Nov 01, 2025

Oct 31, 2025

Price action breakdown for Phathom Pharmaceuticals Inc.Portfolio Update Summary & AI Based Buy and Sell Signals - newser.com

Oct 31, 2025

Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges - TipRanks

Oct 31, 2025

Phathom Pharmaceuticals (PHAT): Forecasts Call for 75% Annual Earnings Growth as Losses Deepen - Yahoo Finance

Oct 31, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 8.9% on Strong Earnings - MarketBeat

Oct 31, 2025

HC Wainwright & Co. Raises Price Target for PHAT to $26.00 | PHA - GuruFocus

Oct 31, 2025

Will Phathom Pharmaceuticals Inc. stock see PE expansionJuly 2025 Summary & Community Verified Swing Trade Signals - newser.com

Oct 31, 2025

Will Phathom Pharmaceuticals Inc. stock reach all time highs in 2025Weekly Trend Report & Daily Technical Forecast Reports - newser.com

Oct 31, 2025

Phathom Pharmaceuticals stock price target raised to $20 by Guggenheim - Investing.com Australia

Oct 31, 2025

Can Phathom Pharmaceuticals Inc. stock sustain market leadershipQuarterly Profit Report & Free Technical Confirmation Trade Alerts - newser.com

Oct 31, 2025

How sentiment analysis helps forecast Phathom Pharmaceuticals Inc.Quarterly Portfolio Report & Accurate Buy Signal Alerts - newser.com

Oct 31, 2025

Phathom Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks

Oct 31, 2025

Oct 30, 2025

Phathom Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat

Oct 30, 2025